Literature DB >> 6083969

Immunohistological study of malignant diffuse mesotheliomas of the pleura.

H Loosli, J Hurlimann.   

Abstract

Paraffin sections from fifteen cases of malignant diffuse mesothelioma of the pleura and five cases of bronchial adenocarcinoma infiltrating the pleura were examined with an antiserum specific for factor VIII related antigen and with antisera against various epithelial markers: keratin, carcinoembryonic antigen (CEA), fat globule membrane antigen and secretory component. In all adenocarcinomas all the epithelial markers were present whereas the factor VIII related antigen was absent. The distribution of the fat globule membrane antigens, keratin, secretory component and factor VIII related antigen varied from one mesothelioma to another. The mesotheliomas were generally negative for CEA. The three mesotheliomas which were positive for CEA were also positive for alcian blue after hyaluronidase treatment. Amongst the markers used, CEA seems the most useful for the differential diagnosis between carcinoma and mesothelioma. However, the simultaneous detection of several markers allows the characterization of various phenotypes. Some of them are close to the phenotypes of true adenocarcinoma. A relation between a given phenotype and the biological behaviour of the tumour has still to be demonstrated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6083969     DOI: 10.1111/j.1365-2559.1984.tb02395.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  13 in total

1.  New marker for mesothelioma: an immunoperoxidase study.

Authors:  A Donna; P G Betta; D Bellingeri; A Marchesini
Journal:  J Clin Pathol       Date:  1986-09       Impact factor: 3.411

2.  Immunohistochemistry in the diagnosis of malignant mesothelioma.

Authors:  M Pfaltz; B Odermatt; B Christen; J R Rüttner
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

3.  Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.

Authors:  K Sheibani; H Battifora; J S Burke
Journal:  Am J Pathol       Date:  1986-05       Impact factor: 4.307

4.  Peritoneal cystic mesothelioma: an electron microscopic and immunohistochemical study of two male patients.

Authors:  I K Sienkowski; A J Russell; S A Dilly; B Djazaeri
Journal:  J Clin Pathol       Date:  1986-04       Impact factor: 3.411

5.  Differences in lectin binding of malignant pleural mesothelioma and adenocarcinoma of the lung.

Authors:  T Kawai; S D Greenberg; L D Truong; C A Mattioli; M Klima; J L Titus
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

6.  Dysphagia due to mesothelioma infiltrating the oesophagus: palliative treatment.

Authors:  C A Lockwood; H W Jones; C K Foote; M J Turner
Journal:  J R Soc Med       Date:  1989-03       Impact factor: 5.344

7.  Loss of polymeric immunoglobulin receptor expression is associated with lung tumourigenesis.

Authors:  Sebahat Ocak; Tetyana V Pedchenko; Heidi Chen; Frederick T Harris; Jun Qian; Vasiliy Polosukhin; Charles Pilette; Yves Sibille; Adriana L Gonzalez; Pierre P Massion
Journal:  Eur Respir J       Date:  2011-09-29       Impact factor: 16.671

8.  Immunocytological staining reactions of anti-carcinoembryonic antigen, Ca, and anti-human milk fat globule monoclonal antibodies on benign and malignant exfoliated mesothelial cells.

Authors:  A K Ghosh; E B Butler
Journal:  J Clin Pathol       Date:  1987-12       Impact factor: 3.411

9.  Diagnostic tools for differentiating between pleural mesothelioma and lung adenocarcinoma in paraffin embedded tissue. Part I: Immunohistochemical findings.

Authors:  H Moch; M Oberholzer; P Dalquen; W Wegmann; F Gudat
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

10.  The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance.

Authors:  G A Blobel; R Moll; W W Franke; K W Kayser; V E Gould
Journal:  Am J Pathol       Date:  1985-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.